Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity
- PMID: 12782590
Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity
Abstract
In this study, using the carcinoembryonic antigen (CEA)-expressing C15 murine colon carcinoma system in syngeneic C57BL/6 mice, we have evaluated the efficacy of bone marrow-derived dendritic cells (DCs) pulsed with the murine anti-idiotype antibody 3H1 as a tumor vaccine. Anti-idiotype 3H1 mimics a distinct and specific epitope of CEA and can generate anti-CEA immunity in mice, rabbits, monkeys, and humans when used with a conventional immune adjuvant. Our goal was to determine whether the use of DC as direct antigen-presenting cells would improve the potency of 3H1 as vaccine. Bone marrow-DC pulsed with 3H1 and injected into naïve mice induced both humoral and cellular anti-3H1, as well as anti-CEA immunity. Specific killing of C15 cells in in vitro antibody-dependent cellular cytotoxicity has been observed by immune sera. Immune-splenic lymphocytes when stimulated in vitro with 3H1 or CEA, showed increased proliferative CD4(+) Th1 type T-cell response and secreted significantly high levels of Th1 cytokines [IFN-gamma, interleukin (IL)-2] and low levels of Th2 cytokines (IL-4, IL-10). This vaccine also induced MHC class I antigen-restricted CD8(+) T-cell responses. The up-regulation of activation markers CD69 and CD25 on CD8(+) CTLs correlated with antigen-specific strong CTL responses in vitro. The immunity induced in mice resulted in a complete rejection of CEA-expressing C15 tumor cells in 100% of experimental mice, whereas no protection was observed when 3H1-pulsed DC-vaccinated mice were challenged with CEA-negative MC-38 cells. The tumor rejection in 3H1-pulsed DC-treated mice was associated with the induction of a memory response that helped those mice to survive a second challenge with a lethal dose of C15 cells.
Similar articles
-
Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.Cancer Res. 2004 Jul 15;64(14):4995-5003. doi: 10.1158/0008-5472.CAN-04-0626. Cancer Res. 2004. PMID: 15256474
-
Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.Cancer Res. 2007 Mar 15;67(6):2881-92. doi: 10.1158/0008-5472.CAN-06-3045. Cancer Res. 2007. PMID: 17363612
-
Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen.Immunology. 2006 Aug;118(4):483-96. doi: 10.1111/j.1365-2567.2006.02391.x. Immunology. 2006. PMID: 16895556 Free PMC article.
-
Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines.Stem Cells. 1997;15(2):94-103. doi: 10.1002/stem.150094. Stem Cells. 1997. PMID: 9090785 Review.
-
Third generation dendritic cell vaccines for tumor immunotherapy.Eur J Cell Biol. 2012 Jan;91(1):53-8. doi: 10.1016/j.ejcb.2011.01.012. Epub 2011 Mar 25. Eur J Cell Biol. 2012. PMID: 21439674 Review.
Cited by
-
Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice.Br J Cancer. 2004 May 17;90(10):2032-41. doi: 10.1038/sj.bjc.6601825. Br J Cancer. 2004. PMID: 15138490 Free PMC article.
-
A novel cancer immunotherapy based on the combination of a synthetic carbohydrate-pulsed dendritic cell vaccine and glycoengineered cancer cells.Oncotarget. 2015 Mar 10;6(7):5195-203. doi: 10.18632/oncotarget.2908. Oncotarget. 2015. PMID: 25760071 Free PMC article.
-
Immunogenic properties of immunoglobulin superfamily members within complex biological networks.Cell Immunol. 2020 Dec;358:104235. doi: 10.1016/j.cellimm.2020.104235. Epub 2020 Oct 11. Cell Immunol. 2020. PMID: 33137645 Free PMC article. Review.
-
CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice.Cancer Immunol Immunother. 2006 May;55(5):515-27. doi: 10.1007/s00262-005-0009-6. Epub 2005 Jul 26. Cancer Immunol Immunother. 2006. PMID: 16044253 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials